Equity

BME

Health Sciences Trust

Overview

Loading

Performance

Performance

  • Returns

  2011 2012 2013 2014 2015
NAV Total Return (%) Total return represents changes to the NAV and accounts for distributions from the fund. 4.92 17.70 36.22 24.86 10.70
Market Price Total Return (%) Market price return represents changes to the fund’s closing market price on its primary exchange and accounts for distributions from the fund. 5.93 21.30 40.04 33.69 8.87

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted.


Returns are shown net of advisory fees paid by the fund and net of the fund’s operating fees and expenses. Investors who purchase shares of the fund through an investment adviser or other financial professional may separately pay a fee to that service provider. Past performance is not indicative of future results.

Growth of Hypothetical $10,000 The growth of hypothetical $10,000 chart reflects a hypothetical $10,000 investment and assumes reinvestment of dividends and capital gains. Fund expenses, including management fees and other expenses were deducted.

Performance chart data not available for display.
View full chart

Distributions

Interactive chart displaying fund performance. Javascript is required.

View full chart

Key Facts

Key Facts

Net Assets as of 26-Sep-2016 $289,042,162
Managed Assets -
Share Class launch date 31-Mar-2005
Exchange New York Stock Exchange Inc.
Asset Class Equity
Morningstar Category Health
Lipper Classification Sector Equity Funds
CUSIP 09250W107
Management Fee 1.00%
Gross Expense Ratio 1.12%
Shares Outstanding as of 26-Sep-2016 8,436,698
Number of Holdings as of 31-Aug-2016 104
3m Avg Volume as of 31-Aug-2016 33,280.00

Holdings

Holdings

as of 31-Aug-2016
Name Weight (%)
MEDTRONIC PLC 5.86
UNITEDHEALTH GROUP INC 5.54
AMGEN INC 4.07
BOSTON SCIENTIFIC CORPORATION 3.73
ALLERGAN PLC 3.17
Name Weight (%)
ELI LILLY AND COMPANY 3.06
PFIZER INC 2.70
JOHNSON & JOHNSON 2.60
BIOGEN INC 2.40
ANTHEM INC 2.20

Exposure Breakdowns

Exposure Breakdowns

as of 31-Aug-2016

% of Market Value Based on Managed Assets

as of 31-Aug-2016

% of Market Value Based on Managed Assets

Geographic exposure relates principally to the domicile of the issuers of the securities held in the product, added together and then expressed as a percentage of the product’s total holdings. However, in some instances it can reflect the country where the issuer of the securities carries out much of their business.
as of 31-Aug-2016

% of Market Value Based on Managed Assets

as of 31-Aug-2016

% of Market Value Based on Managed Assets

Negative weightings may result from specific circumstances (including timing differences between trade and settle dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management.

Allocations are subject to change.

Portfolio Managers

Portfolio Managers

Erin Xie
Managing Director, Lead Portfolio Manager for Health Sciences Investment Strategy Group
Kyle McClements
Managing Director
Thomas Callan
Managing Director
Christopher Accettella
Director
Portfolio Manager

Literature

Literature